Protalix BioTherapeutics, Inc.s in-depth stock price analysis indicates that the stock price has rallied 106.12% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 65.57% . Looking at the past 52 week period, the stock price is up at 28.19% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Protalix BioTherapeutics, Inc. has a negative value of -47.06 compared to overall market performance. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) has climbed 29.49% in the past week and advanced 134.88% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 28.44% and the outperformance has advanced to 130.68% for the last 4 weeks period.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) : On Friday heightened volatility was witnessed in Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) which led to swings in the share price. The stock opened for trading at $0.9782 and hit $1.11 on the upside , eventually ending the session at $1.01, with a gain of 8.21% or 0.0766 points. The heightened volatility saw the trading volume jump to 9,491,873 shares. The 52-week high of the share price is $1.11 and the company has a market cap of $125 million. The 52-week low of the share price is at $0.26 .
Company has reported several Insider transactions to the SEC, on Dec 6, 2016, Capital Management Llc Camber (10% owner) sold 2,500,000 shares at 0.32 per share price.On Dec 15, 2015, Yossi Maimon (CFO) purchased 10,000 shares at 0.78 per share price.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalixs unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalixs first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.